Last reviewed · How we verify
PDE5i arm
At a glance
| Generic name | PDE5i arm |
|---|---|
| Sponsor | Mansoura University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Hypotension
- Dyspepsia
- Gastrooesophageal reflux disease
- Nasopharyngitis
- Diarrhoea
- Fatigue
- Nausea
- Chest pain
- Dizziness
- Constipation
- Upper respiratory tract infection
Key clinical trials
- SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (PHASE2)
- PRP Exosomes Therapy for Erectile Dysfunction (PHASE2)
- PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II) (PHASE4)
- Low Intensity Shockwave Therapy for Erectile Dysfunction (NA)
- A Randomized Trial to Evaluate Efficacy and Safety of Intracavernosal Injection of Platelet-Rich Plasma Versus Phosphodiesterase Type-5 Inhibitors for Treatment of Erectile Dysfunction. (NA)
- Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy (PHASE4)
- Low Energy Shockwave Therapy for Improving Erectile Dysfunction (NA)
- Psychotherapy and Pharmacotherapy in the Treatment of Erectile Dysfunction: A Pilot Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |